Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
JK Altman, JM Foran, KW Pratz, D Trone… - American journal of …, 2018 - Wiley Online Library
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3‐ITD mutations that have high risk of relapse and poor survival …
(AML) harboring FLT3‐ITD mutations that have high risk of relapse and poor survival …
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
JK Altman, JM Foran, KW Pratz… - American Journal …, 2018 - scholars.northwestern.edu
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
JK Altman, JM Foran, KW Pratz, D Trone… - American Journal of …, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Novel therapies have potential to improve
outcomes in patients with acute myeloid leukemia (AML) harboring FLT3‐ITD mutations that …
outcomes in patients with acute myeloid leukemia (AML) harboring FLT3‐ITD mutations that …
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
JK Altman, JM Foran, KW Pratz… - American journal of …, 2018 - pure.johnshopkins.edu
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
JK Altman, JM Foran, KW Pratz… - American Journal …, 2018 - augusta.elsevierpure.com
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
JK Altman, JM Foran, KW Pratz, D Trone… - American Journal of …, 2017 - europepmc.org
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3‐ITD mutations that have high risk of relapse and poor survival …
(AML) harboring FLT3‐ITD mutations that have high risk of relapse and poor survival …
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
JK Altman, JM Foran, KW Pratz… - American journal …, 2018 - mayoclinic.elsevierpure.com
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
[HTML][HTML] Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
JK Altman, JM Foran, KW Pratz, D Trone… - American Journal of …, 2018 - ncbi.nlm.nih.gov
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3‐ITD mutations that have high risk of relapse and poor survival …
(AML) harboring FLT3‐ITD mutations that have high risk of relapse and poor survival …
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
JK Altman, JM Foran, KW Pratz… - American journal …, 2018 - mdanderson.elsevierpure.com
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
JK Altman, JM Foran, KW Pratz… - American journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …
(AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival …